内侧与外侧半月板同种异体移植的中期与长期结果:一项Meta分析
该Meta分析纳入9项研究(内侧半月板同种异体移植287膝、外侧407膝),比较内侧与外侧半月板同种异体移植的中期(5-10年)和长期(>10年)生存率及临床评分。中期与长期生存率在两组间无显著差异,但外侧移植的疼痛评分和Lysholm评分显著高于内侧移植。
要点
- 中期(5-10年)生存率内侧85.8%、外侧89.2%,长期(>10年)生存率内侧52.6%、外侧56.6%。
- 中期和长期生存率在内侧与外侧半月板同种异体移植之间无显著差异。
- 外侧移植的疼痛评分和Lysholm评分显著高于内侧移植。
核心结论
- Meta分析显示,内侧半月板同种异体移植85.8%、外侧89.2%在中长期(5-10年)存活,而内侧52.6%、外侧56.6%在长期(>10年)存活。
- 接受外侧半月板同种异体移植的患者比接受内侧半月板同种异体移植的患者表现出更大的疼痛缓解和功能改善。
研究设计与样本
- 研究设计为Meta分析,共纳入9项研究,包括287膝行内侧半月板同种异体移植和407膝行外侧半月板同种异体移植。
- 纳入的研究评估了随访超过5年的内侧或外侧半月板同种异体移植患者的生存率,并使用疼痛和Lysholm评分等评估来比较术后膝关节结局量表的评分。
- 生存时间定义为转换为膝关节置换术和/或同种异体移植物次全切除术的时间。
主要发现
- 中期(5-10年)生存率评估的膝比例:内侧97/113,外侧108/121,OR 0.71(95% CI,0.31-1.64;P = .42),两组无显著差异。
- 长期(>10年)生存率评估的膝比例:内侧303/576,外侧456/805,OR 0.78(95% CI,0.52-1.17;P = .22),两组无显著差异。
- 中期存活膝比例:内侧半月板同种异体移植85.8%,外侧89.2%;长期存活膝比例:内侧52.6%,外侧56.6%。
- 总体疼痛评分:内侧65.6分,外侧71.3分(95% CI,-3.95至-0.87;P = .002),外侧显著高于内侧。
- Lysholm评分:内侧67.5分,外侧72.0分(95% CI,-10.17至-3.94;P < .00001),外侧显著高于内侧。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It is unclear whether lateral meniscal allograft transplantation (MAT) procedures lead to better clinical outcomes than medial MAT. HYPOTHESIS: The survival rates are similar between medial and lateral MAT, but the clinical outcomes of lateral MAT are better than those of medial MAT at final follow-up. STUDY DESIGN: Meta-analysis. METHODS: In this meta-analysis, we reviewed studies that assessed survival rates in patients who underwent medial or lateral MAT with more than 5 years of follow-up and that used assessments such as pain and Lysholm scores to compare postoperative scores on knee outcome scales. The survival time was considered as the time to conversion to knee arthroplasty and/or subtotal resection of the allograft. RESULTS: A total of 9 studies (including 287 knees undergoing surgery using medial MAT and 407 with lateral MAT) met the inclusion criteria and were analyzed in detail. The proportion of knees in which midterm (5-10 years) survival rates (medial, 97/113; lateral, 108/121; odds ratio [OR] 0.71; 95% CI, 0.31-1.64; P = .42) and long-term (>10 years) survival rates (medial, 303/576; lateral, 456/805; OR 0.78; 95% CI, 0.52-1.17; P = .22) were evaluated did not differ significantly between medial and lateral MAT. In addition, both groups had substantial proportions of knees exhibiting midterm survivorship (85.8% for medial MAT and 89.2% for lateral MAT) but much lower proportions of knees exhibiting long-term survivorship (52.6% for medial MAT and 56.6% for lateral MAT). In contrast, overall pain score (medial, 65.6 points; lateral, 71.3 points; 95% CI, -3.95 to -0.87; P = .002) and Lysholm score (medial, 67.5 points; lateral, 72.0 points; 95% CI, -10.17 to -3.94; P < .00001) were significantly higher for lateral MAT compared with medial MAT. CONCLUSION: Meta-analysis indicated that 85.8% of medial and 89.2% of lateral meniscal allograft transplants survive at midterm (5-10 years) while 52.6% of medial and 56.6% of lateral meniscal allograft transplants survive long term (>10 years). Patients undergoing lateral meniscal allograft transplantation demonstrated greater pain relief and functional improvement than patients undergoing medial meniscal allograft transplantations.
引用
- Bin SI, Nha KW, Cheong JY, et al. Midterm and Long-term Results of Medial Versus Lateral Meniscal Allograft Transplantation: A Meta-analysis. Am J Sports Med. 2017. PMID: 28609637. doi:10.1177/0363546517709777
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。